Andrew Barreto is a Neurology physician affiliated with The University of Texas Health Science Center at Houston. OpenAlex indexes 178 publications with 4,895 citations (h-index 39); ClinicalTrials.gov lists 5 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Vascular Neurology profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
Sponsor: The University of Texas Health Science Center, Houston
- Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke
Sponsor: The University of Texas Health Science Center, Houston
- Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
Sponsor: Andrew D. Barreto, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Balt USA, LLCProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20211 payment
- Xeris Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%SNRI100%Duloxetine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
John Reveille, MD
The University of Texas Health Science Center at Houston
Martin Citardi, MD
The University of Texas Health Science Center at Houston
John Lincoln, MD
The University of Texas Health Science Center at Houston
Frank Arnett, MD
The University of Texas Health Science Center at Houston
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”